CurrentEndo coverage · page 52 of 55

Diabetes, Obesity and Metabolism

Briefs 2,041–2,080 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

Diabetes Obes Metab5 Apr 2023
HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study
Cohort studyT2D & other
Diabetes Obes Metab4 Apr 2023
Glycaemic control and sepsis risk in adults with type 1 diabetes
Cohort studyT1D
Diabetes Obes Metab4 Apr 2023
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study
Randomized controlled trialT2D & other
Diabetes Obes Metab3 Apr 2023
Association between walking pace and incident type 2 diabetes by adiposity level: A prospective cohort study from the UK Biobank
Cohort studyT2D & other
Diabetes Obes Metab3 Apr 2023
Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
Meta-analysisT2D & other
Diabetes Obes Metab3 Apr 2023
High cereal fibre but not total fibre is associated with a lower risk of type 2 diabetes: Evidence from the Melbourne Collaborative Cohort Study
Cohort studyT2D & other
Diabetes Obes Metab31 Mar 2023
Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes
Meta-analysisT2D & other
Diabetes Obes Metab31 Mar 2023
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study
Cohort studyTechnology
Diabetes Obes Metab29 Mar 2023
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence
Research articleT2D & other
Diabetes Obes Metab28 Mar 2023
Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study
Cohort studyT2D & other
Diabetes Obes Metab23 Mar 2023
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry
Cohort studyT2D & other
Diabetes Obes Metab23 Mar 2023
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III , randomized, double‐blind, placebo‐controlled, parallel study
Randomized controlled trialT2D & other
Diabetes Obes Metab23 Mar 2023
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial
Randomized controlled trialT2D & other
Diabetes Obes Metab23 Mar 2023
Trajectory of glycated haemoglobin over time, using real‐world data, in type 2 diabetes patients with obesity on a U‐100 basal‐bolus insulin regimen
Cohort studyT2D & other
Diabetes Obes Metab21 Mar 2023
iGlarLixi (insulin glargine 100 U / ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real‐world data
Meta-analysisT2D & other
Diabetes Obes Metab20 Mar 2023
Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
Secondary analysisT1D
Diabetes Obes Metab17 Mar 2023
COVID ‐19 associated ketosis and diabetic ketoacidosis: A rapid review
Research articleT1D
Diabetes Obes Metab17 Mar 2023
Effect of gastric distension with concurrent small intestinal saline or glucose infusion on incretin hormone secretion in healthy individuals: A randomized, controlled, crossover study
Randomized controlled trial
Diabetes Obes Metab15 Mar 2023
Allometric body shape indices, type 2 diabetes and kidney function: A two‐sample Mendelian randomization study
Research articleT2D & other
Diabetes Obes Metab13 Mar 2023
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
Randomized controlled trialT2D & other
Diabetes Obes Metab13 Mar 2023
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility
Randomized controlled trialObesity
Diabetes Obes Metab13 Mar 2023
Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system
Cohort studyTechnology
Diabetes Obes Metab13 Mar 2023
Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study
Secondary analysisObesity
Diabetes Obes Metab12 Mar 2023
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Cohort studyT2D & other
Diabetes Obes Metab9 Mar 2023
Real‐world impact of once‐weekly subcutaneous semaglutide after 2 years of follow‐up: Results from a nationwide observational study in people with type 2 diabetes
Cohort studyT2D & other
Diabetes Obes Metab9 Mar 2023
Trends and cyclic variation in the incidence of childhood type 1 diabetes in two Italian regions over 33 years and during the COVID ‐19 pandemic
Cohort studyT1D
Diabetes Obes Metab8 Mar 2023
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross‐sectional data
Cross-sectional studyComplications
Diabetes Obes Metab8 Mar 2023
Use of the FreeStyle Libre system and diabetes treatment progression in T2DM : Results from a retrospective cohort study using a Canadian private payer claims database
Cohort studyT2D & other
Diabetes Obes Metab7 Mar 2023
Association between residual islet beta‐cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study
Cross-sectional studyTechnology
Diabetes Obes Metab7 Mar 2023
Burden of liver complications related to non‐alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019
Secondary analysisLipids & liver
Diabetes Obes Metab7 Mar 2023
The importance of targeting multiple risk markers in patients with type 2 diabetes: A post‐hoc study from the CANVAS programme
Secondary analysisT2D & other
Diabetes Obes Metab7 Mar 2023
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study
Cohort studyT2D & other
Diabetes Obes Metab6 Mar 2023
Cardiovascular outcomes trial data from EMPA‐REG OUTCOME , CAROLINA and CARMELINA : Assessment of a novel staging system for type 2 diabetes
Secondary analysisT2D & other
Diabetes Obes Metab6 Mar 2023
Machine learning for non‐invasive sensing of hypoglycaemia while driving in people with diabetes
Diagnostic or prognostic studyT1D
Diabetes Obes Metab3 Mar 2023
A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa ( PACT‐MEA ): Study design and rationale
Trial designT2D & other
Diabetes Obes Metab3 Mar 2023
Prevalence of sleep apnoea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: A French nationwide prospective study
Cohort studyT1D
Diabetes Obes Metab2 Mar 2023
Association between stress hyperglycaemia and in‐hospital cardiac events after coronary artery bypass grafting in patients without diabetes: A retrospective observational study of 5450 patients
Cohort studyT2D & other
Diabetes Obes Metab28 Feb 2023
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis
Meta-analysisT2D & other
Diabetes Obes Metab28 Feb 2023
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia
Secondary analysisT1D
Diabetes Obes Metab28 Feb 2023
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
Randomized controlled trialT2D & other

All 2,200 Briefs in ExploreShowing Briefs 2,041–2,080 of 2,200, newest first